12
EPCLUSA WWW.MEDICALTERMINOLOGY.CO/

Fda approved hepatitis c medicine epclusa

Embed Size (px)

Citation preview

Page 1: Fda approved hepatitis c medicine epclusa

EPCLUSA

WWW.MEDICALTERMINOLOGY.CO/

Page 2: Fda approved hepatitis c medicine epclusa
Page 3: Fda approved hepatitis c medicine epclusa

WWW.MEDICALTERMINOLOGY.CO/

Page 4: Fda approved hepatitis c medicine epclusa

WWW.MEDICALTERMINOLOGY.CO/

Page 5: Fda approved hepatitis c medicine epclusa

WWW.MEDICALTERMINOLOGY.CO/

Page 6: Fda approved hepatitis c medicine epclusa

WWW.MEDICALTERMINOLOGY.CO/

Page 7: Fda approved hepatitis c medicine epclusa
Page 8: Fda approved hepatitis c medicine epclusa
Page 9: Fda approved hepatitis c medicine epclusa

WWW.MEDICALTERMINOLOGY.CO/

Page 10: Fda approved hepatitis c medicine epclusa
Page 11: Fda approved hepatitis c medicine epclusa

WWW.MEDICALTERMINOLOGY.CO

Page 12: Fda approved hepatitis c medicine epclusa

WWW.MEDICALTERMINOLOGY.CO


EPCLUSA FUE MI TIPO DE CURA PARA LA HEPATITIS C · 2020-05-05 · desmayarse, mareos o aturdimiento, malestar general, debilidad, cansancio extremo, disnea, dolor en el pecho, confusión

EPCLUSA FUE MI TIPO DE CURA PARA LA HEPATITIS C · 2020-05-05 · desmayarse, mareos o aturdimiento, malestar general, debilidad, cansancio extremo, disnea, dolor en el pecho, confusión

Documents
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights … · Hepatitis B virus reactivation: Before starting treatment with EPCLUSA, your healthcare provider will do blood tests

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights … · Hepatitis B virus reactivation: Before starting treatment with EPCLUSA, your healthcare provider will do blood tests

Documents
New Therapies For Hepatitis C Therapies for Hepatitis C March 2012 IB 10-429; P96524 Drug Treatments Two new drugs were approved by the U.S. FDA in …Published in: Hepatology · 2007Authors:

New Therapies For Hepatitis C Therapies for Hepatitis C March 2012 IB 10-429; P96524 Drug Treatments Two new drugs were approved by the U.S. FDA in …Published in: Hepatology · 2007Authors:

Documents
205123Orig1s000 - Food and Drug Administration · chronic hepatitis C including pegylated interferon plus ribavirin,boceprevir,and telaprevir. FDA has stated in recent draft guidance

205123Orig1s000 - Food and Drug Administration · chronic hepatitis C including pegylated interferon plus ribavirin,boceprevir,and telaprevir. FDA has stated in recent draft guidance

Documents
Non-Alcoholic Steatohepatitis Hepatitis (NASH) The FDA ......Compensated Cirrhosis NASH Population •Subpopulations –Early cirrhosis without clinically significant portal HTN (i.e.,

Non-Alcoholic Steatohepatitis Hepatitis (NASH) The FDA ......Compensated Cirrhosis NASH Population •Subpopulations –Early cirrhosis without clinically significant portal HTN (i.e.,

Documents
Clinical Policy: Sofosbuvir/Velpatasvir (Epclusa)€¦ · HCV infection and has recently completed at least 60 days of treatment with Epclusa; 2. Member is responding positively to

Clinical Policy: Sofosbuvir/Velpatasvir (Epclusa)€¦ · HCV infection and has recently completed at least 60 days of treatment with Epclusa; 2. Member is responding positively to

Documents
Update on Hepatitis C virus infection · •2011 FDA approved first direct anti viral agent for HCV. Prevalence HCV - Epidemiology United States ... Goals of Hepatitis C Treatment

Update on Hepatitis C virus infection · •2011 FDA approved first direct anti viral agent for HCV. Prevalence HCV - Epidemiology United States ... Goals of Hepatitis C Treatment

Documents
HEPATITIS C: UPDATE AND MANAGEMENT · Professor of Medicine Associate Dean for Educational Improvement Associate ... •I will only be speaking regarding FDA-approved therapies. HEPATITIS

HEPATITIS C: UPDATE AND MANAGEMENT · Professor of Medicine Associate Dean for Educational Improvement Associate ... •I will only be speaking regarding FDA-approved therapies. HEPATITIS

Documents
Clinical Policy: Sofosbuvir/Velpatasvir (Epclusa)...Sofosbuvir/velpatasvir (Epclusa®) is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase

Clinical Policy: Sofosbuvir/Velpatasvir (Epclusa)...Sofosbuvir/velpatasvir (Epclusa®) is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase

Documents
HCV Net Retrospect - Healio/media/images/news/print/hcv-next/... · 2018-12-03 · How the Business of Medicine Affects the Price of Therapy Jun. 28, 2016 FDA approves Epclusa for

HCV Net Retrospect - Healio/media/images/news/print/hcv-next/... · 2018-12-03 · How the Business of Medicine Affects the Price of Therapy Jun. 28, 2016 FDA approves Epclusa for

Documents
ACUTE VIRAL HEPATITIS - vims.ac.in · ACUTE VIRAL HEPATITIS ... Hepatotropic viruses • Hepatitis A • Hepatitis B • Hepatitis C • Hepatitis D, and • Hepatitis E viruses

ACUTE VIRAL HEPATITIS - vims.ac.in · ACUTE VIRAL HEPATITIS ... Hepatotropic viruses • Hepatitis A • Hepatitis B • Hepatitis C • Hepatitis D, and • Hepatitis E viruses

Documents
Eπιπλοκές ERCP: Πρόληψη & αντιμετώπιση Κινητικές ... · 2017-07-27 · μογή της δόσης του Epclusa για ασθενείς με ήπια

Eπιπλοκές ERCP: Πρόληψη & αντιμετώπιση Κινητικές ... · 2017-07-27 · μογή της δόσης του Epclusa για ασθενείς με ήπια

Documents
Hepatitis C, Hepatitis inducida por fármacos y Hepatitis Crónica

Hepatitis C, Hepatitis inducida por fármacos y Hepatitis Crónica

Documents
Arzerra (Ofatumumab): Hepatitis-B-Virus (HBV)-Screening ... · Weitere Informationen: Eine vor Kurzem durchgeführte Analyse der US Food and Drug Aministration (FDA) und betroffener

Arzerra (Ofatumumab): Hepatitis-B-Virus (HBV)-Screening ... · Weitere Informationen: Eine vor Kurzem durchgeführte Analyse der US Food and Drug Aministration (FDA) und betroffener

Documents
FDA-APPROVED HEPATITIS C VIRUS (HCV) DRUGS · FDA-APPROVED HEPATITIS C VIRUS (HCV) DRUGS MUTATIONS IN THE HCV PROTEASE GENE ASSOCIATED WITH RESISTANCE TO NONSTRUCTURAL PROTEIN 3 (NS3)

FDA-APPROVED HEPATITIS C VIRUS (HCV) DRUGS · FDA-APPROVED HEPATITIS C VIRUS (HCV) DRUGS MUTATIONS IN THE HCV PROTEASE GENE ASSOCIATED WITH RESISTANCE TO NONSTRUCTURAL PROTEIN 3 (NS3)

Documents
Majid Talebi Anaraki M.D Gastroentrologist INDEX: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E DRUG-INDUCED HEPATITIS WILSON

Majid Talebi Anaraki M.D Gastroentrologist INDEX: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E DRUG-INDUCED HEPATITIS WILSON

Documents
Viral Hepatitis (Virus Hepatitis)

Viral Hepatitis (Virus Hepatitis)

Documents
Hepatitis C Therapies In the Modern Era: Review for Front-Line Clinicians · 2019. 12. 16. · GLE/PIB (Mavyret) 8 wks SOF/VEL (Epclusa) 12 wks GLE/PIB (Mavyret) 12 wks SOF/VEL (Epclusa)

Hepatitis C Therapies In the Modern Era: Review for Front-Line Clinicians · 2019. 12. 16. · GLE/PIB (Mavyret) 8 wks SOF/VEL (Epclusa) 12 wks GLE/PIB (Mavyret) 12 wks SOF/VEL (Epclusa)

Documents
Food & Beverage Industry Brochure - daemar.com · applications including: FDA Silcone, FDA EPDM, FDA NBR, FDA Neoprene, FDA FKM (Viton), FDA PTFE, FDA PTFE Encapsulated, FFKM (Kalrez)

Food & Beverage Industry Brochure - daemar.com · applications including: FDA Silcone, FDA EPDM, FDA NBR, FDA Neoprene, FDA FKM (Viton), FDA PTFE, FDA PTFE Encapsulated, FFKM (Kalrez)

Documents
Hepatitis C. Characteristics of Viral Hepatitis Hepatitis virus A Hepatitis virus B Hepatitis virus C Hepatitis virus D Hepatitis virus E Incubation (days)

Hepatitis C. Characteristics of Viral Hepatitis Hepatitis virus A Hepatitis virus B Hepatitis virus C Hepatitis virus D Hepatitis virus E Incubation (days)

Documents
New Therapies For Hepatitis C - TN.gov...New Therapies for Hepatitis C March 2012 IB 10-429; P96524 Drug Treatments Two new drugs were approved by the U.S. FDA in May 2011 for treatment

New Therapies For Hepatitis C - TN.gov...New Therapies for Hepatitis C March 2012 IB 10-429; P96524 Drug Treatments Two new drugs were approved by the U.S. FDA in May 2011 for treatment

Documents
Hepatitis E in humans - VISAVET Pere… · VIRAL HEPATITIS Those caused by different viruses with primary tropism for the liver tissue Hepatitis A Hepatitis B Hepatitis C Hepatitis

Hepatitis E in humans - VISAVET Pere… · VIRAL HEPATITIS Those caused by different viruses with primary tropism for the liver tissue Hepatitis A Hepatitis B Hepatitis C Hepatitis

Documents
(+) Stranded RNA Viruses III RNA Hepatitis Viruses Hepatitis A, Hepatitis C, Hepatitis E, Hepatitis G D- virology

(+) Stranded RNA Viruses III RNA Hepatitis Viruses Hepatitis A, Hepatitis C, Hepatitis E, Hepatitis G D- virology

Documents
A Hepatitis C Primer for Non-Treaters · A Hepatitis C Primer for Non-Treaters John F. Reinus, M.D. Medical Director of Liver Transplantation ... FDA-approved all-oral treatment regimens

A Hepatitis C Primer for Non-Treaters · A Hepatitis C Primer for Non-Treaters John F. Reinus, M.D. Medical Director of Liver Transplantation ... FDA-approved all-oral treatment regimens

Documents
FDA Presentation FDA Presentation

FDA Presentation FDA Presentation

Documents
Treating Hepatitis C -HIV CoinfectedPatients · FDA Approved NS5B inhibitor Sofosbuvir(Solvadi) QD Pangenotypic 2013 NS3A protease ... (Epclusa) QD Pangenotypic 2016. Case 1 A 52

Treating Hepatitis C -HIV CoinfectedPatients · FDA Approved NS5B inhibitor Sofosbuvir(Solvadi) QD Pangenotypic 2013 NS3A protease ... (Epclusa) QD Pangenotypic 2016. Case 1 A 52

Documents
Treatment of Genotype 2, 3 ,4, and Beyonds3.gi.org/meetings/na2016/16ACG_Hep_School_Southern_0006.pdf · ACG 2016 Southern Hepatitis School ... • Open-label trial; ... ,Epclusa

Treatment of Genotype 2, 3 ,4, and Beyonds3.gi.org/meetings/na2016/16ACG_Hep_School_Southern_0006.pdf · ACG 2016 Southern Hepatitis School ... • Open-label trial; ... ,Epclusa

Documents
1 FDA Review Perspective – Entecavir for Hepatitis B Linda L. Lewis, M.D. Medical Officer Division of Antiviral Drug Products

1 FDA Review Perspective – Entecavir for Hepatitis B Linda L. Lewis, M.D. Medical Officer Division of Antiviral Drug Products

Documents
EPCLUSA: NOW APPROVED FOR MORE · THE FIRST PANGENOTYPIC REGIMEN FOR PATIENTS AGED 6 AND OLDER EPCLUSA: NOW APPROVED FOR MORE PATIENTS WITH CHRONIC HCV1 INDICATION EPCLUSA (sofosbuvir

EPCLUSA: NOW APPROVED FOR MORE · THE FIRST PANGENOTYPIC REGIMEN FOR PATIENTS AGED 6 AND OLDER EPCLUSA: NOW APPROVED FOR MORE PATIENTS WITH CHRONIC HCV1 INDICATION EPCLUSA (sofosbuvir

Documents
Specialty Pipeline MONTHLY UPDATE...Specialty Pipeline Monthly Update: April 2020 Page 3 NEW INDICATIONS Epclusa® (sofosbuvir and velpatasvir): The FDA broadened the use of Gilead

Specialty Pipeline MONTHLY UPDATE...Specialty Pipeline Monthly Update: April 2020 Page 3 NEW INDICATIONS Epclusa® (sofosbuvir and velpatasvir): The FDA broadened the use of Gilead

Documents